Crossmark

Cardiac sodium channel mutations: why so many phenotypes?

Crossref DOI link: https://doi.org/10.1038/nrcardio.2014.85

Published Online: 2014-06-24

Published Print: 2014-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Man

Yang, Kai-Chien

Dudley, Samuel C. Jr
License Information

Text and Data Mining valid from 2014-06-24
More Information

Article History

First Online: 24 June 2014

Competing interests

: S.C.D. is the inventor on patents or patent applications: SCN5A splice variants for use in methods relating to sudden cardiac death and need for implanted cardiac defibrillators (PCT/US2012/20564); SCN5A splicing factors and splice variants for use in diagnostic and prognostic methods (US 13/291,826); Modulation of sodium channels by nicotinamide adenine dinucleotide (US 8,003,324); Human sodium channel isoforms (US 11/707,882); Method for modulating or controlling sodium channel current by reactive oxygen species (US 12/929,786); Activation of the renin–angiotensin system (RAS) and sudden cardiac death (US 13/032,629); Modulation of sodium channels by nicotinamide adenine dinucleotide (US 13/067,953); and Method for detecting Brugada syndrome (US 61/786,882). S.C.D. founded a company called 3PrimeDx to commercialize a blood test for sudden death risk. The other authors declare no competing interests.